Sikarin Public Company (SKR) Fair Value & Analysis
Healthcare · TH · Market cap 14.8B THB
Fair value as of: Jun 24, 2026
Analysis
Sikarin Public Company (SKR) currently trades at 7.70 THB, while our model-based Fair Value estimate is 8.15 THB — implying the stock looks roughly 5.8% undervalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Sikarin Public Company Limited, together with its subsidiaries, operates hospitals in Thailand. The company operates diabetes and endocrine center, general medicine clinic, emergency and trauma center, surgery clinic, children's dental center, aesthetic center, laboratory department, diagnostic radiology center, CT scan unit, operating rooms, hemodialysis units, physical therapy department with physical medicine and rehabilitation specialist, catheter laboratory, intensive care units, coronary care units, inpatient wards and international wards, after heart and thoracic surgery ward, medical-surgical ward, and pediatric ward. It also operates woman's health center, health center, fertility center, delivery room, nursery department and the inpatient wards, obstetrics and gynecology ward, stroke center, EENT center, international medical center, orthopedics center, and MRI center. In addition, the company is involved in the management of rental spaces; and sale of food and beverages, …
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Sikarin Public Company (SKR) undervalued?
What is the fair value of SKR?
What is the quality score of SKR?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.